Metastatic Melanoma Clinical Trials

57 recruitingLast updated: June 17, 2026

There are 57 actively recruiting metastatic melanoma clinical trials across 19 countries. Studies span Phase 2, Phase 1, Not Applicable, Phase 3, Phase 4, Early Phase 1. Top locations include Los Angeles, California, United States, New York, New York, United States, Pittsburgh, Pennsylvania, United States. Updated daily from ClinicalTrials.gov.


Metastatic Melanoma Trials at a Glance

57 actively recruiting trials for metastatic melanoma are listed on ClinicalTrialsFinder across 6 cities in 19 countries. The largest study group is Phase 2 with 23 trials, with the heaviest enrollment activity in Los Angeles, New York, and Pittsburgh. Lead sponsors running metastatic melanoma studies include Iovance Biotherapeutics, Inc., M.D. Anderson Cancer Center, and National Cancer Institute (NCI).

Browse metastatic melanoma trials by phase

Treatments under study

About Metastatic Melanoma Clinical Trials

Looking for clinical trials for Metastatic Melanoma? There are currently 54 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Metastatic Melanoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Metastatic Melanoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 57 trials

Recruiting
Phase 1Phase 2

Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer

Clinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8Metastatic Melanoma+10 more
National Cancer Institute (NCI)16 enrolled26 locationsNCT05896839
Recruiting
Phase 1Phase 2

A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel

Metastatic MelanomaUnresectable MelanomaOcular Melanoma
Iovance Biotherapeutics, Inc.42 enrolled5 locationsNCT06940739
Recruiting
Phase 1Phase 2

A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer

Metastatic MelanomaUnresectable MelanomaStage IV Non-Small Cell Lung Cancer+1 more
Iovance Biotherapeutics, Inc.53 enrolled11 locationsNCT05361174
Recruiting
Phase 4

Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study

Metastatic Head and Neck Squamous Cell CarcinomaMetastatic Hepatocellular CarcinomaMetastatic Lung Non-Small Cell Carcinoma+18 more
OHSU Knight Cancer Institute160 enrolled1 locationNCT07405086
Recruiting
Phase 2

Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors

Anatomic Stage IV Breast Cancer AJCC v8Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8+26 more
M.D. Anderson Cancer Center50 enrolled1 locationNCT04771520
Recruiting
Phase 1Phase 2

Natural Killer Cell Therapy (UD TGFbetai NK Cells) and Temozolomide for the Treatment of Stage IV Melanoma Metastatic to the Brain

Clinical Stage IV Cutaneous Melanoma AJCC v8Metastatic MelanomaPathologic Stage IV Cutaneous Melanoma AJCC v8+1 more
Kari Kendra24 enrolled1 locationNCT05588453
Recruiting
Phase 3

Duration of Anti-PD-1 Therapy in Metastatic Melanoma

Unresectable/Metastatic Melanoma
Canadian Cancer Trials Group614 enrolled30 locationsNCT02821013
Recruiting
Phase 1Phase 2

MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma

Metastatic MelanomaMelanoma Stage IVMelanoma Stage III+1 more
Perspective Therapeutics300 enrolled13 locationsNCT05655312
Recruiting
Phase 2

BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study

Clinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8Metastatic Head and Neck Squamous Cell Carcinoma+22 more
National Cancer Institute (NCI)150 enrolled222 locationsNCT05136196
Recruiting
Phase 1

A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

Locally Advanced Hepatocellular CarcinomaLocally Advanced MelanomaMetastatic Hepatocellular Carcinoma+7 more
National Cancer Institute (NCI)30 enrolled1 locationNCT06066138
Recruiting
Phase 1

IL-17 Blockade to Decrease irAEs (REPLAY)

Metastatic Melanoma
Duke University4 enrolled1 locationNCT07237594
Recruiting
Phase 1Phase 2

Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis

Metastatic MelanomaLiver Metastases
University of Wisconsin, Madison15 enrolled1 locationNCT07281924
Recruiting
Phase 2

Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma

Metastatic MelanomaMetastatic Renal Cell CarcinomaAdvanced Locoregional Melanoma+1 more
National Cancer Institute (NCI)78 enrolled1 locationNCT05155033
Recruiting
Phase 1

A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, or Dedifferentiated Liposarcoma

MelanomaMetastatic MelanomaUveal Melanoma+1 more
Memorial Sloan Kettering Cancer Center30 enrolled2 locationsNCT05607095
Recruiting
Early Phase 1

Study of CBL0137 in Combination With Ipilimumab and Nivolumab Therapy in Melanoma

Locally Advanced or Metastatic Melanoma
Fox Chase Cancer Center12 enrolled1 locationNCT05498792
Recruiting
Phase 2

Cryoablation+Ipilimumab+Nivolumab in Melanoma

Metastatic MelanomaSkin Cancer
Massachusetts General Hospital37 enrolled1 locationNCT05779423
Recruiting
Phase 1

Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease

Clinical Stage IV Cutaneous Melanoma AJCC v8Metastatic Lung Non-Small Cell CarcinomaMetastatic Melanoma+7 more
M.D. Anderson Cancer Center75 enrolled1 locationNCT03025256
Recruiting
Phase 3

Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain

Anatomic Stage IV Breast Cancer AJCC v8Metastatic Breast CarcinomaMetastatic Lung Non-Small Cell Carcinoma+7 more
NRG Oncology269 enrolled263 locationsNCT06500455
Recruiting
Phase 1Phase 2

Safety and Efficacy of OBX-115 in Advanced Solid Tumors

Lung CancerMelanomaNon-small Cell Lung Cancer+4 more
Obsidian Therapeutics, Inc.208 enrolled9 locationsNCT06060613
Recruiting
Not Applicable

Physical Activity Directly Before Immunotherapy (Nivolumab and Ipilimumab) in Melanoma

Metastatic Melanoma
Universitätsklinikum Hamburg-Eppendorf40 enrolled1 locationNCT07564570